The RIO Trial is a randomised placebo-controlled trial of Antiretroviral Therapy (ART) plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary or Early stage HIV Infection on viral control off ART.

The objective is to test the hypothesis that for individuals who commenced antiretroviral therapy (ART) in primary or early stage HIV infection (PHI), a combination of the two long-acting broadly neutralising antibodies, 3BNC117-LS and 10-1074-LS, will induce a period of virological remission when ART is stopped compared with participants who received ART plus placebo.